Editorial: Molecular biomarkers of cardiometabolic disease.

This article is an editorial published in Frontiers in Endocrinology that discusses the importance of molecular biomarkers in the diagnosis and prognosis of cardiometabolic disease (CMD). CMD refers to a combination of metabolic and cardiovascular diseases, with insulin resistance playing a central role in its development. The article highlights the challenges in managing CMD due to its diverse manifestations and the absence of reliable molecular biomarkers. The editorial presents nine original research articles that explore potential biomarkers for CMD, including serum low-density lipoprotein receptor-related protein 1 (sLRP1), atrial natriuretic peptide (ANP), energy metabolism-related genes (EMRGs), serum testosterone (TT), SLCO1B1 rs4149056, fetuin-A, lipid-lowering drug targets, hyperhomocysteinemia (HHcy), and the molecular mechanism underlying the association between type 2 diabetes mellitus (T2DM) and atherosclerosis. The authors suggest that further research is needed to refine our understanding of CMD biomarkers and their diagnostic and prognostic value. [Extracted from the article]